featured
Dr. Mark Lebwohl on Emerging Therapies for Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Predicting Treatment Response in Psoriasis Using Serum Levels of Adalimumab and Etanercept: A Single-Centre, Cohort Study
- Undertreatment, Treatment Trends, and Treatment Dissatisfaction Among Patients With Psoriasis and Psoriatic Arthritis in the United States: Findings From the National Psoriasis Foundation Surveys, 2003-2011
- Counseling Patients on Psoriasis Treatment
-
Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3):546-551.
-
Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nature Rev Drug Discov. 2012;11:763-776.
-
Zhang J, Xie F, Delzell E. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43-49.
-
Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60:1001-1017.